Perceptions of COVID-19 Vaccination in Patients with Genitourinary Cancers: A Survey Study.

Humans COVID-19 / prevention & control COVID-19 Vaccines / adverse effects Urogenital Neoplasms Vaccination
COVID-19 vaccine genitourinary cancer survey study vaccine hesitancy

Journal

Cancer investigation
ISSN: 1532-4192
Titre abrégé: Cancer Invest
Pays: England
ID NLM: 8307154

Informations de publication

Date de publication:
Jan 2023
Historique:
pubmed: 15 10 2022
medline: 24 1 2023
entrez: 14 10 2022
Statut: ppublish

Résumé

Since the approval of the COVID-19 vaccines, their safety and efficacy has been widely demonstrated in patients with cancer. However, there remain patients with reservations regarding vaccination. We aimed to assess genitourinary cancer patients' perceptions of the vaccines as well as barriers and influencers of decision-making through the completion of a questionnaire. While vaccine-associated concerns were observed, most patients with genitourinary cancers were willing to receive the vaccine. Moving forward, differing strategies could be considered to enhance patient education on the utility of vaccination in the setting of cancer and beyond.

Identifiants

DOI: 10.1080/07357907.2022.2136683 PMID: 36239609
pubmed: 36239609
doi: 10.1080/07357907.2022.2136683
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

70-76

Auteurs

Daniela V Castro (DV)

Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
ORCID: 0000-0002-5423-9821

Zeynep B Zengin (ZB)

Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA.

Jasnoor Malhotra (J)

Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA.

Cristiane D Bergerot (CD)

Centro de Câncer de Brasília (CETTRO), Instituto Unity de Ensino e Pesquisa, Brasília, Brazil.
ORCID: 0000-0003-0037-0303

Luis Meza (L)

Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA.

Nazli Dizman (N)

Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Yale University School of Medicine, New Haven, Connecticut, USA.

Ameish Govindarajan (A)

Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA.

JoAnn Hsu (J)

Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA.

Alex Chehrazi-Raffle (A)

Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA.

Neal Chawla (N)

Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA.

Benjamin D Mercier (BD)

Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA.

Sean W Chen (SW)

Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA.

Matthew Feng (M)

Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA.

Sweta Prajapati (S)

Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA.

Kyle O Lee (KO)

Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
ORCID: 0000-0002-9361-3804

Errol J Philip (EJ)

University of California San Francisco (UCSF) School of Medicine, San Francisco, California, USA.

Tanya B Dorff (TB)

Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA.

Yung Lyou (Y)

Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA.

Sumanta K Pal (SK)

Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Perceptions of COVID-19 Vaccination in...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Perceptions of COVID-19 Vaccination in...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins contre la COVID-19 › Perceptions of COVID-19 Vaccination in...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Perceptions of COVID-19 Vaccination in...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Prévention primaire › Immunisation › Vaccination › Perceptions of COVID-19 Vaccination in...